Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MYOC | Q99972 | 1/20 | 0.40 |
| ▸ | DDX3X | O00571 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814139 | 0.88 | KMT2A (0.44) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2816759 | 0.88 | MAPT (0.51) | MAPTMEN1KMT2ANPSR1MYOC | |
| SCHEMBL13133013 | 0.87 | MEN1 (0.43) | MAPTMEN1KMT2ANPSR1MYOC | |
| SCHEMBL2814969 | 0.86 | FLT3 (0.43) | MAPTMEN1KMT2ANTRK1GAA | |
| SCHEMBL2813764 | 0.83 | CCNC (0.39) | MAPTMEN1KMT2ANPSR1NTRK1 | |
| SCHEMBL2813744 | 0.82 | HRH3 (0.41) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2816415 | 0.81 | HRH3 (0.40) | MAPTMEN1KMT2ANTRK1GAA | |
| SCHEMBL2818220 | 0.80 | SAE1 (0.42) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2814136 | 0.80 | KMT2A (0.42) | MAPTMEN1KMT2ASMN1; SMN2RET | |
| SCHEMBL2815380 | 0.79 | MEN1 (0.57) | MAPTMEN1KMT2ANTRK1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | MAPT 3810/4885MEN1 171/4885KMT2A 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.